Omeros ROE 2009-2019 | OMER

Current and historical return on equity (ROE) values for Omeros (OMER) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested. Omeros ROE for the three months ending September 30, 2019 was 0.00%.
Omeros ROE - Return on Equity Historical Data
Date TTM Net Income Shareholder's Equity Return on Equity
2019-09-30 $-0.08B $-0.14B 63.54%
2019-06-30 $-0.10B $-0.13B 91.82%
2019-03-31 $-0.12B $-0.12B 132.24%
2018-12-31 $-0.13B $-0.10B 185.40%
2018-09-30 $-0.12B $-0.09B 271.19%
2018-06-30 $-0.09B $-0.06B 445.57%
2018-03-31 $-0.07B $-0.03B 348.72%
2017-12-31 $-0.05B $-0.00B 218.56%
2017-09-30 $-0.06B $0.01B 170.99%
2017-06-30 $-0.06B $-0.06B 154.60%
2017-03-31 $-0.06B $-0.05B 157.96%
2016-12-31 $-0.07B $-0.04B 181.33%
2016-09-30 $-0.07B $-0.02B 195.68%
2016-06-30 $-0.07B $-0.05B 236.80%
2016-03-31 $-0.08B $-0.04B 458.82%
2015-12-31 $-0.08B $-0.03B 6080.00%
2015-09-30 $-0.08B $-0.01B 1400.00%
2015-06-30 $-0.08B $0.01B 750.00%
2015-03-31 $-0.08B $0.02B 515.25%
2014-12-31 $-0.07B $-0.04B 389.47%
2014-09-30 $-0.06B $-0.03B 431.37%
2014-06-30 $-0.05B $-0.01B 425.00%
2014-03-31 $-0.05B $0.01B 383.67%
2013-12-31 $-0.04B $-0.02B 228.57%
2013-09-30 $-0.05B $-0.02B 311.86%
2013-06-30 $-0.05B $-0.01B 500.00%
2013-03-31 $-0.04B $-0.02B 355.56%
2012-12-31 $-0.04B $-0.01B 371.43%
2012-09-30 $-0.04B $-0.00B 400.00%
2012-06-30 $-0.04B $-0.02B 388.89%
2012-03-31 $-0.03B $-0.01B 2480.00%
2011-12-31 $-0.03B $-0.01B -504.35%
2011-09-30 $-0.03B $0.00B -212.24%
2011-06-30 $-0.03B $0.01B -158.82%
2011-03-31 $-0.03B $0.02B -136.36%
2010-12-31 $-0.03B $0.02B -109.09%
2010-09-30 $-0.03B $0.02B -87.22%
2010-06-30 $-0.03B $0.03B -104.17%
2010-03-31 $-0.02B $0.04B -139.39%
2009-12-31 $-0.02B $0.04B -289.66%
2009-06-30 $-0.02B $0.00B inf%
Sector Industry Market Cap Revenue
Medical Medical Products Manufacturing $0.691B $0.030B
Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros' most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgery(TM) clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders.
Stock Name Country Market Cap PE Ratio
Abbott Laboratories (ABT) United States $149.063B 27.19
Medtronic (MDT) Ireland $149.019B 20.57
Stryker (SYK) United States $77.484B 26.05
Boston Scientific (BSX) United States $59.419B 28.05
Baxter (BAX) United States $41.697B 25.28
EssilorLuxottica Societe Anonyme (ESLOY) France $33.939B 0.00
Zimmer Biomet Holdings (ZBH) United States $29.730B 18.65
Terumo (TRUMY) Japan $27.062B 33.77
Coloplast (CLPBY) Denmark $25.790B 41.17
Lonza Group Ag (LZAGY) Switzerland $24.991B 0.00
ResMed (RMD) United States $21.480B 39.63
Smith & Nephew SNATS (SNN) United Kingdom $18.946B 0.00
Sunny Optical Technology (SNPTF) China $17.912B 0.00
Insulet (PODD) United States $11.183B 532.03
Bio-Rad Laboratories (BIO) United States $10.900B 52.32
Hill-Rom Holdings (HRC) United States $7.158B 21.10
William Demant Holdings (WILYY) Denmark $6.665B 0.00
Perrigo (PRGO) Ireland $6.631B 12.36
DiaSorin S.p.A (DSRLF) Italy $6.420B 0.00
Haemonetics (HAE) United States $6.124B 41.38
Shandong Weigao Medical Polymer (SHWGF) China $5.382B 0.00
Canopy Growth (CGC) Canada $5.338B 0.00
GN STORE NORD (GNNDY) Denmark $5.276B 27.26
ICU Medical (ICUI) United States $3.781B 24.65
NuVasive (NUVA) United States $3.774B 29.72
Neogen (NEOG) United States $3.369B 56.37
GW Pharmaceuticals (GWPH) United Kingdom $3.199B 0.00
Hutchison China MediTech (HCM) Hong Kong, SAR China $3.183B 0.00
Quidel (QDEL) United States $2.720B 25.81
Aurora Cannabis (ACB) Canada $2.407B 0.00
Agios Pharmaceuticals (AGIO) United States $2.157B 0.00
National Vision Holdings (EYE) United States $2.155B 48.64
InMode (INMD) Israel $1.785B 0.00
Cardiovascular Systems (CSII) United States $1.578B 0.00
AtriCure (ATRC) United States $1.143B 0.00
VAREX IMAGING (VREX) United States $1.132B 22.68
Aphria (APHA) $1.084B 0.00
Phibro Animal Health (PAHC) United States $0.941B 17.61
NanoString Technologies (NSTG) United States $0.858B 0.00
Lantheus Holdings (LNTH) United States $0.829B 20.72
Eagle Pharmaceuticals (EGRX) United States $0.793B 30.37
TG Therapeutics (TGTX) United States $0.790B 0.00
LeMaitre Vascular (LMAT) United States $0.689B 38.70
PetIQ (PETQ) United States $0.669B 16.32
Quanterix (QTRX) United States $0.649B 0.00
Cerus (CERS) United States $0.606B 0.00
Surmodics (SRDX) United States $0.529B 55.20
OraSure Technologies (OSUR) United States $0.472B 28.33
HEXO (HEXO) $0.468B 0.00
MacroGenics (MGNX) United States $0.424B 0.00
Owens & Minor (OMI) United States $0.400B 14.79
Utah Medical Products (UTMD) United States $0.382B 27.68
Meridian Bioscience (VIVO) United States $0.374B 12.87
Organigram Holdings (OGI) Canada $0.362B 0.00
BioLife Solutions (BLFS) United States $0.310B 126.17
Zynex (ZYXI) United States $0.292B 33.04
Neptune Wellness Solutions (NEPT) Canada $0.254B 0.00
Viemed Healthcare (VMD) United States $0.234B 0.00
Bovie Medical (APYX) United States $0.231B 0.00
Vapotherm (VAPO) United States $0.230B 0.00
United Health Products (UEEC) United States $0.226B 0.00
Repro-Med Systems (KRMD) United States $0.166B 0.00
InfuSystems Holdings (INFU) United States $0.147B 740.00
Cytosorbents (CTSO) United States $0.135B 0.00
Rockwell Medical (RMTI) United States $0.132B 0.00
Fonar (FONR) United States $0.130B 9.18
Liberty Health Sciences (LHSIF) Canada $0.128B 0.00
Female Health (VERU) United States $0.124B 0.00
Chimerix (CMRX) United States $0.118B 0.00
United-Guardian (UG) United States $0.088B 22.27
Chembio Diagnostics (CEMI) United States $0.075B 0.00
Nephros (NEPH) United States $0.063B 0.00
MRI Interventions (MRIC) United States $0.058B 0.00
MTech Acquisition (KERN) United States $0.055B 0.00
Oramed Pharmaceuticals (ORMP) United States $0.043B 0.00
Surface Oncology (SURF) United States $0.040B 0.00
ImmuCell (ICCC) United States $0.036B 0.00
Trinity Biotech (TRIB) Ireland $0.023B 0.00
Senestech (SNES) United States $0.018B 0.00
GUARDION HEALTH (GHSI) United States $0.014B 0.00
Valeritas Holdings (VLRX) United States $0.013B 0.00
Conatus Pharmaceuticals (CNAT) United States $0.011B 0.00
Myomo (MYO) United States $0.009B 0.00
Capricor Therapeutics (CAPR) United States $0.007B 0.00
NeuroMetrix (NURO) United States $0.003B 0.00
Akers Biosciences Inc (AKER) United States $0.003B 0.00